PRMA Insights: The Roadmap to Pricing and Reimbursement Success

The psoriasis report delivers

Use this report to gain an understanding of the following issues in the pricing and reimbursement of psoriasis in the major markets:

• The key pricing and reimbursement issues and treatments by country and the implications for biologics seeking indications for psoriasis is now critical to commercial success.
• How payers have critically evaluated the data packages for existing biologics for psoriasis.
• An in-depth critical review of over 25 pricing and reimbursement and HTA assessments in psoriasis in the major markets.
• The price existing products have achieved and their reimbursement status in each country.
• The value propositions and arguments manufacturers have submitted for their products.
• A review of the recent risk sharing agreement for Stelara in the UK.
• An overview of psoriasis with a focus on the key issues shaping the market access landscape.
• The implications surrounding the choice of comparators and endpoints included in the clinical trials in pricing and reimbursement.
• A comprehensive review of biologics, regulatory indications, key supporting data packages and the position in clinical guidelines.
• The key learnings and market access insights for developing a new biologic in psoriasis.
• A review of the epidemiology and burden of psoriasis with insights into evidence gaps and the impact on your health outcomes strategy.
• A review of the existing instruments used to measure PRO’s in psoriasis, opportunities for the inclusion of PRO data in your label and how this could differentiate your product and impact pricing and reimbursement.
  
  

Find out more about the psoriasis report:

The report delivers         Scope of the report        Authors of the report